Investors in Medical Devices

The MVC manages a €10 million fund by investing equity in start-up companies operating within the digital economy and innovative economic sectors that contribute significant value to the Maltese economy. Eligible companies may include those involved in video game development, fintech, e-sports, life sciences, pharma, green energy, the filming industry, agritech, AI, communications, electronics, financial services, medical devices, software, bluewater industries, and digital technology. Start-up companies operating in innovative economic sectors will have access to the newly established fund, with each start-up being eligible for up to €500,000 in the form of equity investment. The investment by the fund will be pari-passu with that of private venture capital investors. The Malta Government Venture Capital Limited will be the sole entity responsible for administering this scheme.

Vivalto Partners is an independent European management company approved by the Autorité des Marchés Financiers, specializing in investment in the healthcare sector. We invest in profitable SMEs and mid-cap companies and support their managers in their development projects, in capital and through strategic and operational support. Founded in 2021 by Daniel Caille, a pioneering figure in private healthcare in France, Vivalto Partners brings together healthcare experts and investment professionals in an approach to supporting players who contribute to the quality of care to meet the major challenges of transforming the sector in Europe.

Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world's most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies.

BrainDTech is focused on the early diagnosis and monitoring of neurological and neurodegenerative disorders, leveraging advanced technology and innovative research. By providing accurate and timely insights, BrainDTech aims to improve patient outcomes and quality of life. Their commitment to excellence drives the development of cutting-edge solutions in the field of neurology.

Cur8 Capital is a trading name of IFG.VC Limited, a subsidiary of Islamicfinanceguru Limited. IFG.VC Limited is authorised and regulated by the FCA (No. 943736). Cur8 Capital provides a platform showcasing various investment opportunities, though it does not promote any specific investment to the public. The information presented is meant to demonstrate the types of investments available. Detailed campaigns are accessible to authorised investors on the Cur8 Capital platform. Investment activities are confined to the United Kingdom, and potential investors outside the UK should verify local regulations. This page does not offer financial or tax advice, as tax treatment varies per individual circumstances and may change.

Eurovestech PLC is an AIM-listed pan-European development capital fund that specializes in investing in high-technology enterprises. The firm focuses on identifying and supporting innovative companies across Europe with high growth potential, particularly in sectors such as technology and digital media. Eurovestech provides strategic development capital to help these enterprises accelerate their growth, expand their market presence, and achieve their strategic objectives. As a publicly listed company on the AIM market, Eurovestech offers investors the opportunity to participate in the growth of promising high-tech businesses through transparent and regulated investment vehicles. The firm's investment strategy emphasizes active management and value creation, aiming to maximize shareholder value while supporting the development of transformative technologies and businesses.

Rosetta Capital Limited operates as a private equity and venture capital firm specializing in direct secondary investments. The firm focuses on acquiring direct stakes in private companies from existing shareholders, providing liquidity and growth capital to support these businesses. Rosetta Capital's investment strategy involves identifying attractive opportunities in established companies with strong growth potential and sustainable business models. By leveraging its expertise in direct secondary transactions, the firm aims to generate value and foster growth within its portfolio companies. Rosetta Capital plays a crucial role in the secondary market, facilitating transactions that enable shareholders to realize value while positioning portfolio companies for continued success and expansion.

Samen Slimmer is an investment firm dedicated to fostering innovation by strategically backing visionary startups and scalable businesses. They leverage expertise and resources to propel growth, emphasizing sustainable development and impactful contributions across sectors. Operating proactively, they seek promising opportunities aligned with their investment criteria and strategic objectives.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.

Endeavour Vision is a leading venture capital and growth equity advisory firm focusing on commercial-stage medtech and digital health companies. We support transformative healthcare technologies that provide superior clinical benefits for patients or bring significant efficiencies to health systems. Our team offers strategic and operational expertise and extensive international experience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Relievant Medsystems, Vertiflex, and Symetis, as well as several IPOs. Endeavour Vision's international investment teams are located in Geneva, Switzerland, Minneapolis, US and San Francisco, US.

Vivalto Partners is an independent European management company approved by the Autorité des Marchés Financiers, specializing in investment in the healthcare sector. We invest in profitable SMEs and mid-cap companies and support their managers in their development projects, in capital and through strategic and operational support. Founded in 2021 by Daniel Caille, a pioneering figure in private healthcare in France, Vivalto Partners brings together healthcare experts and investment professionals in an approach to supporting players who contribute to the quality of care to meet the major challenges of transforming the sector in Europe.

Vivalto Partners is an independent European management company approved by the Autorité des Marchés Financiers, specializing in investment in the healthcare sector. We invest in profitable SMEs and mid-cap companies and support their managers in their development projects, in capital and through strategic and operational support. Founded in 2021 by Daniel Caille, a pioneering figure in private healthcare in France, Vivalto Partners brings together healthcare experts and investment professionals in an approach to supporting players who contribute to the quality of care to meet the major challenges of transforming the sector in Europe.